The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2.
Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.
Gore
M E
ME
Department of Medicine, Royal Marsden Hospital, London, U.K.
Galligioni
E
E
Keen
C W
CW
Sorio
R
R
Loriaux
E M
EM
Grobben
H C
HC
Franks
C R
CR
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
D007376:Interleukin-2; D011994:Recombinant Proteins